北京若生智能科技有限公司
Drug Database
AT

atenolol + nifedipine (nifedipine/atenolol / Bresben / Niften)

✓ Approved

AstraZeneca UK Limited · ADRB1 · 小分子

什么是 atenolol + nifedipine？

atenolol + nifedipine 是一种小分子，由AstraZeneca UK Limited研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名nifedipine/atenolol, Bresben, Niften
公司AstraZeneca UK Limited
药物类别小分子
分子靶点ADRB1, CACNA1C
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, AstraZeneca UK Limited

作用机制

分子靶点

atenolol + nifedipine 作用于 2 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CaV1.2, CACNL1A1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atenolol + nifedipine 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedJournal of drug targeting2026-09-06

Ufasomal Nanocarriers for Enhanced Cardiac Delivery of Nifedipine: A Novel Strategy to Mitigate Doxorubicin-Induced Cardiotoxicity in Breast Cancer Therapy.

Farouk Hanan O HO, Abo El-Ela Fatma I FI, Baali Fahad H FH, Belal Amany A et al.

The cardiotoxicity of doxorubicin significantly restricts its effectiveness, even though it remains a crucial element of breast cancer chemotherapy. Nifedipine (NFP) offers multi-mechanistic therapeutic benefits, including vasodilation, anti-proliferative activities, suppression of cellular apoptosis, and potent anti-inflammatory and antioxidant properties. However, the translation of oral NFP into an effective cardioprotective adjuvant is hindered by its poor solubility, first-pass hepatic metabolism, and poor bioavailability. Hence, this study aimed to develop a nasal NFP-loaded ufasomes (NLU) spray formulation to enhance the permeation, bioavailability, sustained release, and cardiac accumulation of NFP when co-administered with doxorubicin. Various NLU formulations were developed and optimized employing Design-Expert® software. The in vivo cardioprotective efficacy of the nasal NLU was comprehensively evaluated in a doxorubicin-induced cardiotoxicity rat model. The optimal NLU substantially prolonged drug sustainability and amplified mucosal permeability by 69.07% and 6.47-fold, respectively, compared to the free NFP suspension. Furthermore, nasal NLU formulation achieved a remarkable 7.33-fold enhancement in bioavailability and a 5.40-fold increase in cardiac tissue accumulation when contrasted with conventional oral NFP administration. Furthermore, the nasal NLU spray exhibited superior cardioprotective and antioxidant performance over the oral NFP. In conclusion, these findings establish the nasal NLU formulation as a promising therapeutic platform to mitigate doxorubicin-induced cardiotoxicity.

PMID 42700144
阅读全文 →
PubMedInternational journal of surgery case reports2026-09-06

The role of integrated radiology in diagnosis and treatment of renal artery stenosis: a case report.

Wahyono Djuwita Adi DA, Darmawan Marsha Ruthy MR, Drajat Endang E, Praptini Mirna Nurasri MN et al.

Renal artery stenosis (RAS) is a significant cause of ischemic nephropathy and secondary hypertension and is often underdiagnosed. While atherosclerosis predominates in older adults, younger patients are affected by various etiologies, such as fibromuscular dysplasia (FMD). Early diagnosis and intervention using integrated radiologic modalities are crucial to prevent irreversible end-organ damage in such patients. A 16-year-old male presented with a 6-month history of dizziness and refractory hypertension, with peak readings above 190/100 mm Hg despite aggressive antihypertensive therapy (amlodipine, nifedipine, and spironolactone). His physical examination was unremarkable except for elevated blood pressure (140/100 mmHg). Computed tomography angiography (CTA) of the renal arteries revealed a tight focal stenosis in the right renal artery, with post-stenotic dilation and collateral circulation to both poles of the right kidney. Selective digital subtraction angiography (DSA) confirmed these findings. Percutaneous transluminal renal angioplasty (PTRA) was performed using sequentially larger balloons (2.5 mm to 5.0 mm), and a vascular stent was deployed, achieving complete recanalization and robust distal flow. The patient was discharged on dual antiplatelet therapy with no complaints. This case highlights the utility of CTA for detailed anatomical assessment and DSA for confirmation and intervention. The need for stenting post-angioplasty due to residual stenosis underscores the importance of having a comprehensive endovascular strategy. Early and effective management of RAS is crucial to prevent long-term complications in young patients. Integrated imaging is essential for diagnosis, lesion characterization, and procedural planning in RAS patients. Endovascular revascularization is an effective treatment with early technical and clinical success.

PMID 42699528
阅读全文 →
PubMedJournal of drugs in dermatology : JDD2026-09-04

Topical Sirolimus for Refractory Cutis Marmorata Telangiectatica Congenita in Adulthood: A Case Report.

Bhatt Ram D RD, Karpoff Kateryna K, Heitman Nicholas N, Aslam Rabail R et al.

Cutis marmorata telangiectatica congenita (CMTC) is a rare congenital vascular disorder characterized by persistent, violaceous, reticulated skin changes that may be complicated by painful ulcerations. Although localized disease often improves with age, generalized CMTC can persist into adulthood and may be associated with limb asymmetry, ocular abnormalities, and neurologic sequelae. Diagnosis can be challenging in atypical adult presentations despite established major and minor criteria. We report a case of a 50-year-old woman with congenital livedo reticularis and Raynaud syndrome who presented with lifelong unilateral left lower-extremity hypoplasia and fixed lacy violaceous patches. Over the preceding decade, she developed recurrent, spontaneous, painful ulcerations exacerbated by cold exposure. Examination revealed a hypoplastic left leg with reticulated violaceous patches and tender, crusted erosions without venectasia; biopsy findings ruled out vasculitis, and the overall clinicopathologic picture met all three major and multiple minor Kienast-Hoeger criteria for CMTC. Multiple therapies targeting vasospasm and microvascular flow (including sildenafil, pentoxifylline, diosmiplex, nifedipine, and aspirin) failed to improve symptoms. Initiation of once-daily topical sirolimus (1 mg/mL) resulted in marked pain reduction within four weeks and cessation of new ulcerations, with visible improvement and healed erosions by two months. This case supports topical sirolimus as a promising off-label option for adult CMTC with chronic ulcerative disease.

PMID 42696321
阅读全文 →
PubMedNihon yakurigaku zasshi. Folia pharmacologica Japonica2026-09-03

[Revolutionizing physiology: advances in organ-on-a-chip technology].

Li Qiang Q, Takahashi Ken K

To address the low predictability (92% clinical failure rate) and high costs associated with species differences in traditional animal testing, this research advocates for New Approach Methodologies (NAMs) in alignment with the US FDA Modernization Act 2.0. The central achievement presented is the development of a "human Heart-on-a-chip." This microfluidic device co-cultures human iPS-derived cardiomyocytes, fibroblasts, and vascular endothelial cells to mimic living 3D tissue structures and fluid environments. The system demonstrated superior physiological reproducibility compared to conventional methods in evaluating drug responses (e.g., nifedipine) and detecting fatal side effects like QT prolongation. In addition to the heart, applications are advancing across diverse organ and disease models, including the construction of ischemia-reperfusion injury models using kidney chips and pulmonary fibrosis models using lung chips, the evaluation of barrier functions via blood-brain barrier (BBB) chips, and the analysis of interactions between cancer cells and immune cells using cancer chips. It is concluded that these technologies enable high-precision in vitro reproduction of human physiology and pathology, thereby improving the efficiency of drug screening, reducing economic losses, and accelerating the paradigm shift toward the 3Rs (Replacement, Reduction, and Refinement) in animal experimentation.

PMID 42686555
阅读全文 →
PubMedAnalytical chemistry2026-09-03

An Analyte-Specific LC-IMS-HRMS Framework for Enhanced Identification Confidence in Target Screening of Contaminants in Complex Matrices.

Diamanti Konstantina S KS, Damalas Dimitrios E DE, Gkotsis Georgios O GO, Panagopoulou Eleni I EI et al.

Reliable identification of contaminants in complex matrices remains hampered by low-abundance signals, complex spectra, and coeluting isobars in liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analyses with data-independent acquisitions. Moreover, wide-scope target screening workflows covering hundreds to thousands of known compounds from reference standards analyses often fail to fully exploit the acquired data, leading to false positives and false negatives. Herein, trapped ion mobility spectrometry (TIMS) was integrated into LC-HRMS, and an enriched database and an analyte-specific framework were introduced for enhanced identification confidence. The database including 1948 contaminants incorporated all MS and MS/MS qualifier ions together with their CCS values and mobility filtering windows, alongside the principal ion. Specific qualifiers were designated as mandatory for the first time by evaluating their relative intensity compared to the principal ion (≥50%), with the established identification points systems being refined accordingly to increase confidence. Regarding TIMS data, ∼2500 CCS values were determined, exhibiting high repeatability (RSD ≤ 0.70%) and interinstrument reproducibility (|ΔCCS|≤ 2%). Comparison with literature data across different IMS-HRMS platforms showed CCS accuracy within 2% for 89% of the ions. In matrix spiking experiments (raptor's eggs, human urine, wastewater), the cleaner mobility-filtered spectra resulted in improved selectivity for several contaminants' qualifiers, which improved detection at low concentrations, minimizing false negatives. Additionally, both differentiation based on CCS values (e.g., atenolol-practolol) and mandatory detection of predefined qualifiers (e.g., prometryn-terbutryn) decreased false positives. By incorporating the TIMS dimension and mandatory qualifiers as additional identification information, this work provides a robust framework for high-throughput environmental monitoring and human exposure assessment.

PMID 42689556
阅读全文 →
PubMedPloS one2026-09-03

Immobilized horseradish peroxidase hybrid biocatalysts for degradation of pharmaceuticals and other emerging micropollutants.

Al-Maqdi Khadega A KA, Morsi Rana R, Zhou Hao H, Abdussaitova Assina A et al.

With the increasing detection of emerging pollutants (EPs), such as pharmaceuticals, personal care products, and pesticides, in water bodies, there is a growing research priority to develop efficient methods for their degradation. In the present study, the degradation of 21 EPs from different classes was investigated using horseradish peroxidase (HRP) covalently immobilized onto two photocatalytic supports, TiO2 and ZnO. The hybrid biocatalysts (TiO2-HRP and ZnO-HRP) were used to degrade EPs with and without the presence of a redox mediator, 1-hydroxybenzotriazole (HOBT). The results revealed that not all EPs were equally degraded by HRP enzymes, with some pollutants showing complete, partial, or no degradation. For example, full degradation was achieved for MBT (100%), meloxicam (99.5%) and caffeic acid (98.6%). In contrast, prometryn and MCPA showed only partial degradation, reaching 19.2% and 20%, respectively, and no degradation was observed for fluometuron and atenolol. The addition of the model redox mediator, HOBT, improved the degradation of some pollutants, for example, lincomycin-HCl degradation increased to 36.9%, while trimethoprim degradation improved to 21.5%. Additionally, several pollutants, including roxithromycin, cimetidine, and caffeine, exhibited significantly higher degradation rates when treated with the immobilized HRP enzyme (TiO2-HRP or ZnO-HRP) compared to free HRP. For instance, roxithromycin degradation increased from 0.5% to 58.2% with ZnO-HRP, and for cimetidine, TiO₂-HRP improved degradation from 0.3% to 60.1% without HOBT and from 9.0% to 66.7% with HOBT. Molecular docking with the catalytic heme cofactor retained further suggested that degradation trends were not explained by docking score alone, but were influenced by ligand access to the distal heme pocket, molecular planarity, and contact topology near catalytic residues. Finally, an integrated HRP enzyme and chemical oxidation remediation strategy was applied to degrade two pollutants, trimethoprim and DEET. For trimethoprim, TiO2-HRP combined with H2O2 and UV achieved approximately 30% degradation, while for DEET, both TiO2-HRP + H2O2 + UV and ZnO-HRP + H2O2 + UV resulted in around 40% degradation, thereby highlighting a novel application for these hybrid peroxidase-photocatalysts.

PMID 42685069
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多atenolol + nifedipine